title: DAPT duration after DES: what is the "mandatory" duration?
authors: The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Roxana.Mehran@mountsinai.org.
authors: Roxana
authors: R
authors: Mehran
authors: The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
authors: Gennaro
authors: G
authors: Giustino
authors: The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
authors: Usman
authors: U
authors: Baber
mesh_terms: D054855:Drug-Eluting Stents; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*
chemical_list: D010975:Platelet Aggregation Inhibitors
keywords: bleeding; major adverse cardiac event(s); stent thrombosis